FDC manufactures allopathic pharmaceutical preparations. The company operates in manufacturing and marketing of oral re hydration salts (ORS) and ophthalmics. The company has also set-up globally approved, multi-location manufacturing facilities for active pharmaceuticals ingredients (APIs) as well as finished dosage forms.
The stock broke out of a consolidation base on very good volume and is trading in an ideal buy zone. The key level of trend is at 241 and the critical level at 230. The stock has witnessed minor selling pressure and has found support near its previous high at 272. The ideal entry zone is between 272 and 285. With an invalidation level of 248 the stock has a potential to move towards the zone of 326 and 338.
Disclaimer
All investments involve risk, and the past performance of a security, industry, sector, market, financial product, trading strategy, or individual’s trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. Such decisions should be based solely on an evaluation of their financial circumstances, investment objectives, risk tolerance, and liquidity needs.
The stock broke out of a consolidation base on very good volume and is trading in an ideal buy zone. The key level of trend is at 241 and the critical level at 230. The stock has witnessed minor selling pressure and has found support near its previous high at 272. The ideal entry zone is between 272 and 285. With an invalidation level of 248 the stock has a potential to move towards the zone of 326 and 338.
Disclaimer
All investments involve risk, and the past performance of a security, industry, sector, market, financial product, trading strategy, or individual’s trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. Such decisions should be based solely on an evaluation of their financial circumstances, investment objectives, risk tolerance, and liquidity needs.
Comment:
The stock was recommended on June 30 as the stock broke out of the consolidation base on very good volume.Today stock made a low of 247 and closed below the 50 DMA. The stop-loss should be placed below today low at 247 and one should exit from this stock on price breaching the levels of 247. Though its fundamental have not deteriorated, we will be exiting the stock below 247 with a loss of 8.2 percent on account of technical weakness.
Trade closed: stop reached:
The low of the prior day low at 247 is breached. Exit the stock with a loss of 8.2 percent on account of technical weakness.